Strive Financial Group
LENZ icon

Strive Financial Group’s LENZ Therapeutics LENZ Stock Holding History

Strive Financial Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$384 Buy
+100
New +$498 ﹤0.01% 1169

Other funds holding LENZ

Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Strive Financial Group's LENZ Position: Q3 2026 in Review

Strive Financial Group opened a new position in LENZ Therapeutics (LENZ) in Q3 2026: 100 shares worth $384. The stake represents ﹤0.01% of the portfolio and ranks #1169 among its holdings.

55 funds tracked by Wall St. Rank hold LENZ as of Q3 2026.

  • Strive Financial Group held 100 shares of LENZ Therapeutics worth $384 as of Q3 2026.
  • LENZ Therapeutics was a new Strive Financial Group position in Q3 2026.
  • LENZ Therapeutics made up ﹤0.01% of Strive Financial Group's portfolio in Q3 2026, its #1169 holding.
  • 55 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2026.

Based on Strive Financial Group's 13F filing for Q3 2026, filed 9 Nov 2026.